1 2

# Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularis

3

Ahmad Rajeh<sup>1</sup>, Hannah L. Cornman<sup>1</sup>, Anuj Gupta<sup>2</sup>, Mindy D. Szeto<sup>1</sup>, Anusha Kambala<sup>1</sup>, Olusola
 Oladipo<sup>1</sup>, Varsha Parthasarathy<sup>1</sup>, Junwen Deng<sup>1</sup>, Sarah Wheelan<sup>3</sup>, Thomas Pritchard<sup>1</sup>, Madan
 M. Kwatra<sup>4</sup>, Yevgeniy R. Semenov<sup>5,6</sup>, Alexander Gusev<sup>7,8</sup>, Srinivasan Yegnasubramanian<sup>2,9</sup>,

- M. Kwatra<sup>4</sup>, Yevgeniy R. Semenov<sup>5,6</sup>, Alexander Gusev<sup>7,8</sup>, Srinivasan Ye
   Shawn G. Kwatra<sup>1,9</sup>
- , 8

20

30

- <sup>1</sup>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD,
   USA.
- <sup>2</sup>The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
- <sup>3</sup>Present affiliation: National Human Genome Research Institute, National Institute of Health,
   Bethesda, MD, USA.
- <sup>4</sup>Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA.
- <sup>5</sup>Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
- <sup>6</sup>Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
- <sup>7</sup>Division of Genetics, Brigham & Women's Hospital, Boston, MA, USA.
- <sup>18</sup> <sup>8</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- <sup>9</sup>Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- 21 **Corresponding author:**
- 22 Shawn G. Kwatra, MD
- 23 Associate Professor of Dermatology and Oncology
- 24 Director, Johns Hopkins Itch Center
- 25 Johns Hopkins University School of Medicine
- 26 Office: Room 206, Lab: Suite 216, Koch CRBII
- 27 1550 Orleans Street, Baltimore, MD 21231, USA
- 28 Tel: 410-955-8662
- 29 Email: <u>skwatra1@jhmi.edu</u>

# 31 Conflict-of-interest statement

S.G.K. is an advisory board member/consultant for Abbvie, Aslan Pharmaceuticals, Arcutis
 Biotherapeutics, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte
 Corporation, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron

- 35 Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Pfizer, Incyte,
- and Sanofi. S.Y. receives research funding to his institution from Bristol-Myers Squibb and
- 37 Celgene, Janssen, and Cepheid for unrelated work and has served as a consultant for Cepheid.
- He owns founder's equity in Brahm Astra Therapeutics and Digital Harmonic. All other authors
- 39 declare they have no competing interests.
- 40

It is made available under a CC-BY-NC-ND 4.0 International license .

# 41 Abstract

42	Prurigo nodularis (PN) is a chronic inflammatory skin disease that disproportionately
43	affects African Americans and is characterized by pruritic skin nodules of unknown
44	etiology. Little is known about genetic alterations in PN pathogenesis, especially relating
45	to somatic events which are often implicated in inflammatory conditions. We thus
46	performed whole-exome sequencing on 54 lesional and nonlesional skin biopsies from
47	17 PN patients and 10 atopic dermatitis (AD) patients for comparison. Somatic
48	mutational analysis revealed that PN lesional skin harbors pervasive somatic mutations
49	in fibrotic, neurotropic, and cancer-associated genes. Nonsynonymous mutations were
50	most frequent in NOTCH1 and the Notch signaling pathway, a regulator of cellular
51	proliferation and tissue fibrosis, and NOTCH1 mutations were absent in AD. Somatic
52	copy-number analysis, combined with expression data, showed that recurrently deleted
53	and downregulated genes in PN lesional skin are associated with axonal guidance and
54	extension. Follow-up immunofluorescence validation demonstrated increased NOTCH1
55	expression in PN lesional skin fibroblasts and increased Notch signaling in PN lesional
56	dermis. Finally, multi-center data revealed a significantly increased risk of NOTCH1-
57	associated diseases in PN patients. In characterizing the somatic landscape of PN, we
58	uncover novel insights into its pathophysiology and identify a role for dysregulated
59	Notch signaling in PN.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 61 Introduction

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic skin nodules on the trunk and extremities (1, 2). Compared to more common and better characterized chronic pruritic dermatoses like atopic dermatitis (AD) or psoriasis, PN is associated with greater itch intensity (3), as well as a significant quality of life impairment (4, 5). PN emerges in middle age, disproportionately affects African Americans, and is associated with multiple systemic conditions (6–9). Despite this significant clinical burden, the etiology of PN remains poorly understood.

69 The current understanding of PN biology centers around an interplay between 70 cutaneous inflammation, neuronal dysregulation, and altered keratinocyte differentiation and 71 fibroblast signaling (10–13). Recent transcriptomic studies show characteristic patterns of 72 immune polarization in PN patients, including both Th2/Th17-centered cutaneous immune 73 activation, and cutaneous and systemic Th22-related cytokine upregulation (10, 14). Black 74 patients have a greater genetic risk of developing PN and distinct inflammatory signatures are 75 seen in African American PN patients, suggesting the existence of multiple disease endotypes 76 (15–17). However, to which extent those patterns might be explained by genetic variation or 77 environmental exposures remains unknown. In better studied chronic pruritic dermatoses such 78 as AD and psoriasis, genomic studies have accelerated our understanding of disease pathology 79 and informed new treatments (18, 19), but similar investigations are lacking for PN.

The relevance of genomic studies in inflammatory skin disease includes postzygotic variation. Somatic mutations throughout the body are known to drive neoplasms, but growing evidence also points to clonal expansions harboring somatic mutations in non-neoplastic disease and healthy-appearing tissue, including the skin (20–23). Such findings have informed our understanding of both the disease and the corresponding tissue biology. For example, colonic mucosa of patients with inflammatory bowel disease displays positive selection for

It is made available under a CC-BY-NC-ND 4.0 International license .

86 mutations in interleukin-17 pathway genes, which may confer a protective advantage to mucosal 87 epithelia (20, 24). Thus, delineating somatic events associated with PN may further our 88 understanding of not only disease pathology, but also cutaneous molecular adaptations in the 89 setting of chronic itch, fibrosis, and neuroinflammation. This is especially pressing given the 90 comorbidities in PN patients, including a higher risk of skin and internal malignancies (25, 26), 91 which remain largely unexplained.

92 In this study, we characterize the landscape of somatic events in PN lesional skin. We 93 perform whole-exome sequencing (WES) on individual-matched lesional and nonlesional skin 94 biopsies from a diverse cohort of PN patients, as well as AD patients as a reference group. We 95 explore the mutational landscape of PN at the individual nodule level, identifying somatic events 96 in lesional PN skin compared to adjacent healthy-appearing skin. We also contrast the somatic profile of PN to that of AD to elucidate molecular pathways specific to PN. Our somatic analysis 97 also leads us to functional and multi-center epidemiological follow-up investigations. To our 98 99 knowledge, this work represents the first and largest genomic study of PN.

100

#### 101 **Results**

#### 102 Whole-exome analysis

An illustration of the study design is shown (Figure 1A). Briefly, we recruited 17 patients from the Johns Hopkins Itch Center diagnosed with PN (Figure 1B and C) fulfilling our selection criteria (see Methods). Patient demographics are summarized in Figure 1D. Two skin punchbiopsies were obtained from each patient, one from a prurigo nodule (lesional) and one from normal-appearing skin (nonlesional) within 10 cm of the nodule. Since high-throughput WES can provide sufficient resolution for the detection of somatic events, we generated WES data from 17 lesional and 17 nonlesional PN samples in this study. In the same method, we also

It is made available under a CC-BY-NC-ND 4.0 International license .

generated 20 matched WES datasets from 10 patients with AD for use as reference group(Figure 1A and D).

112	From our PN cohort (34 WES datasets across 17 patients), we obtained approximately
113	1.7 billion reads (mean and range = $4.9 \times 10^7 [4.2 \times 10^7 \text{ to } 6.1 \times 10^7]$ and $5.2 \times 10^7 [4.3 \times 10^7 \text{ to } 10^7]$
114	$7.0 \times 10^7$ ] for lesional and nonlesional samples, respectively). After quality control and alignment
115	to the hg38 human reference genome, we noted an average sequencing coverage of 195 (187
116	and 202 for lesional and nonlesional, respectively). On average, more than 93% of the exome
117	was sequenced to at least 20X depth, providing a reliable signal for variant calling (27). Detailed
118	sequencing and alignment information, including results from preprocessing and variant calling
119	on our AD control cohort, is provided (Table S1). One pair of AD lesional/nonlesional samples
120	was excluded from downstream analyses because the nonlesional sample had less than 50% of
121	the exome sequenced to at least 20X depth.

122

### Somatic variation in PN lesional skin

123 Somatic variants in PN nodules were identified by matching PN lesional to nonlesional 124 samples per patient. The landscape of somatic mutations in PN is shown in Figure 1E-H. 125 Following guality control, we identified 2387 high-confidence somatic single nucleotide variations (SNVs) SNVs and small insertions/deletions (indels) in PN lesional skin affecting 126 127 1933 genes. Mutational analysis showed a median of 75 somatic (lesion-specific) mutations per patient, including SNVs and indels. We observed a median mutational burden of approximately 128 129 0.52 per megabase of coding region (range of 0.26 to 9 per megabase; outlier sample was 130 further characterized in Figure S1). We noted 35% (847 of 2387), 2.0% (48 of 2387), 0.59% (14 of 2387), 0.58% (13 of 2387), and 0.3% (8 of 2387) missense, nonsense, splice site altering, in-131 frame indels, and frameshift indels, respectively. After predicting the effects of variants on 132 133 protein function, variants were classified into significance categories "High + Moderate", 134 indicating likely change in protein sequence, and "Low + Modifier", indicating no known change

It is made available under a CC-BY-NC-ND 4.0 International license .

in protein sequence (Figure 1F). We found a median of 29 functional, lesion-specific somatic
 SNVs or indels per PN patient (range of 13 to 450) (Figure 1F).

We observed a median somatic variant allele frequency (VAF) of 0.031 (range of 0.01 to 137 138 0.449) in PN lesional skin, with Caucasian PN patients displaying a higher VAF than African American PN patients (0.033 compared to 0.029, P = 0.0056, *Wilcoxon*) (Figure 1G and H). On 139 140 assessment of somatic variants at the gene level, there were 46 genes with nonsynonymous 141 somatic mutations in at least two out of 17 patients with PN. We grouped recurrently-mutated genes using three a priori-defined gene sets relevant to PN based on literature and clinical 142 judgement. There were 5 genes associated with pathologic fibrosis (NOTCH1, SCN5A, MAP1B, 143 144 TTN, ITPR1) (28), 6 genes associated with neuronal migration or projection (MAP1B, RELN, 145 TENM1, CNTN2, NAV1, RGS12) by gene ontology, and 4 cancer-associated genes (NOTCH1, TRRAP, FAT1, NCOA1) according to the Cancer Gene Census (CGC) from the Catalogue of 146 147 Somatic Mutations in Cancer (COSMIC) (29). NOTCH1 had the most frequent nonsynonymous 148 somatic mutations: we found 4 missense SNVs (p.Arg1962His, p.Asn70lle, p.Glu450Lys, and 149 p.Asn325Lys) and 1 in-frame deletion (p.Val413-Asp414del) across 4 patients, 2 of whom were 150 African American. NOTCH1 is an intracellular regulator of the Notch family with pleiotropic 151 functions in cellular proliferation and tissue fibrosis, and a known hallmark driver of cutaneous 152 squamous cell carcinoma (cSCC) (30, 31). 3 out of 5 identified NOTCH1 mutations where within 153 the extracellular epidermal growth factor (EGF)-like domain, which is involved in ligand binding and preventing constitutional activation (32). Somatic mutations in NOTCH1 had a significant 154 155 co-occurrence with mutations in NCOA1, MISP, NAV1, MYO1C, RGS12, and VPS13B (P < 156 0.05, pairwise Fisher's exact test) (Figure 2A). 157 Genes associated with fibrosis. In addition to NOTCH1, we identified somatic mutations

in other profibrotic genes. We noted two missense mutations in SCN5A (p.Gly1158Asp,

p.Arg1638Gln) across two PN patients. SCN5A encodes the alpha subunit of the Na<sub>v</sub>1.5 sodium

It is made available under a CC-BY-NC-ND 4.0 International license .

160	channel, which plays a key role in the depolarization of cardiomyocytes and whose				
161	channelopathy is linked to cardiac fibrosis (33). SCN10A from the same gene family, which				
162	encodes $Na_v 1.8$ , which regulates pro-inflammatory responses in the skin and was significantly				
163	upregulated in the epidermis of rosacea and psoriasis skin lesions (34).				
164	We found two missense mutations in <i>ITPR1</i> (p.Ala805Val, p.Glu914Lys) affecting two				
165	PN patients. ITPR1 encodes one of the three members of the IP3-receptor family that form				
166	calcium release channels and is associated with pancreatic fibrosis (28), in addition to chronic				
167	itch mediated by astrocytes (35). We also observed two recurrent missense mutations in				
168	MAP1B (p.Val1549Gly x 2) across two patients. While MAP1B is thought to be primarily				
169	involved in microtubule assembly and neurogenesis, it also plays a role in fibrosis, particularly in				
170	the eye (28, 36).				
171	In addition, we found TTN mutated in 3 patients including 4 missense mutations				
172	(p.Ala25524Val, p.Asn8023Lys, p.Ala35193Thr, and p.Val7022Ala) and one frame-shift deletion				
173	(p.Val29546AsnfsTer3). TTN has an established role in interstitial fibrosis and is frequently				
174	mutated in numerous cancers, but it encodes the largest protein in humans and is frequently				
175	mutated in reference populations (37, 38). Of note, we found a recurrent p.lle1690Val missense				

176 mutation in Epiplakin 1 (*EPPK1*) in 3 of the PN patients. While *EPPK1* was not in our pre-

- defined gene sets, this was the only gene with 3 or more identical recurrent somatic mutations,
- 178 at either the DNA or amino acid level. *EPPK1* encodes a member of the plakin family which is
- 179 involved in the organization of cytoskeletal architecture and has been shown to accelerate
- 180 keratinocyte migration during wound healing (39, 40). We also found several mutations in genes
- related to neuronal migration or projection, detailed below.
- 182 *Neurotropic genes.* The mutations in *MAP1B* are described above since it is found to 183 have both fibrotic as well as neurotropic functions (28, 36). *RELN*, which is involved in nerve 184 migration, projection, and synaptic plasticity was found to have two missense mutations

It is made available under a CC-BY-NC-ND 4.0 International license .

185	(p.Thr468Pro, p.Val167Leu) across two patients. We also found two missense mutations across					
186	two patients in TENM1 (p.Ala2661Ser, p.Gly1134Arg) and CNTN2 (p.Ala2661Ser,					
187	p.Gly1134Arg). TENM1 encodes a protein of the teneurin subfamily which is thought to function					
188	as a neuronal cellular signal transducer and is one of the most highly mutated genes in					
189	melanoma (41). CNTN2 encodes contactin 2, which is found to play an important role in					
190	neuronal excitability (42). In addition, we noted two missense mutations across two patients in					
191	RGS12 (p.Gly454Asp, p.Arg403Cys) and NAV1 (p.Pro1507Ser, p.Arg1581Cys). RGS12 was					
192	shown to be a critical modulator of serotonergic neurotransmission (43), while NAV1 is a					
193	relatively understudied gene that is involved in neuronal development and regeneration (44).					
194	Cancer-associated genes. To identify mutations in known cancer genes, we overlapped					
195	our set of 46 genes with recurrent nonsynonymous mutations and the curated CGC gene list					
196	from COSMIC (29). We found recurrent mutations in known cancer genes TRRAP, FAT1, and					
197	NCOA1. We found 3 missense mutations in TRRAP (p.Pro252Ser, p.Pro1364Leu,					
198	p.Glu2479Lys) across two patients. TRRAP is involved a cell-cycle regulation and oncogenesis					
199	and has been found to be recurrently mutated in melanoma (45, 46). Notably, previous work					
200	showed that skin fibroblasts of individuals with TRRAP mutations have significant changes in					
201	expression of genes associated with neuronal function and ion transport (45). FAT1, a regulator					
202	of cell-cell adhesion and extracellular matrix architectural integrity that is a recognized driver of					
203	cSCC (47), had one nonsense p.Gln2076Ter mutation and one splice site mutation across two					
204	patients. We also found two missense mutations in NCOA1 (p.Pro1102Ser, p.Ala498Thr) across					
205	two PN patients.					
206	We further investigated the mutation rate in known oncogenic pathways as reported by					
207	The Cancer Genome Atlas (48). We found the Notch signaling pathway to be most commonly					
208	mutated in our PN cohort, with variants detected in 9 out of 17 patients (52.9%), including					

209 mutations in NOTCH1, NOTCH4, CNTN6, FBXW7, JAG2, and SPEN. Notch signaling is

Rajeh et al.

It is made available under a CC-BY-NC-ND 4.0 International license .

followed by the RTK-RAS and Wnt pathways, which were altered in 5 (29.4%) and 4 (23.5%)
PN patients, respectively. A list of high-confidence somatic SNV and indel calls made in this
study is included in Table S2.

*Gene set enrichment analysis.* Gene set enrichment analysis offers a relatively unbiased view into the somatic landscape at the pathway level and can highlight patterns that are too subtle to identify at the gene level (49). As a proxy for the somatic selection, we first conducted an enrichment analysis of high-VAF (>0.3) nonsynonymous somatic mutations. Different patterns by race were observed (Figure 2). Notably, high-VAF mutations in African American PN patients were associated with epithelial-to-mesenchymal transition (*NOTCH4* and *TASOR*; FDR-adjusted P < 0.05).

220 We then performed enrichment analysis of all genes that were found to have recurrent 221 nonsynonymous somatic mutations in PN lesions. We included pathways from 3 term 222 databases: Gene Ontology (GO) Biological Process, GO Cellular Component, and NCI-Nature 223 Pathways. After correction for multiple hypothesis testing, the most significantly mutated 224 networks were related to Notch-mediated signaling, neuronal migration, and polymeric 225 cytoskeletal fiber (Figure2, B-D).

226 Since we identified *NOTCH1* as the most frequently mutated gene in PN lesional skin, 227 and loss-of-function mutations in NOTCH1 have been established to occur commonly in cSCC (50), we compared our PN somatic calls to a publicly available cSCC variant dataset from a 228 229 recent metanalysis by Chang et al. (47). We included 83 cSCC samples for this analysis, with a 230 median tumor mutational burden and VAF of 21.4 per megabase and 0.258, respectively. Not surprisingly, cSCC samples had a significantly higher mutational burden and VAF than our PN 231 samples (P < 0.001, Wilcoxon) (Figure 3A and B). NOTCH1 was mutated in 55.4% of cSCC 232 233 samples, second only to TTN. Overall, there were 6 genes that mutated in 25% or more of the 234 cSCC samples and also in two or more samples of our PN cohort: NOTCH1, FAT1, TTN, FLG,

It is made available under a CC-BY-NC-ND 4.0 International license .

and *RELN* (Figure 3C-E). Out of those genes, *NOTCH1* and *FAT1*, are the ones previously
identified as likely cSCC drivers (47) (Figure 3C-E). In addition, *TASOR2*, a gene found to be
differentially regulated in several cancers but whose function remains understudied (51), was
the only gene not mutated in any of the cSCC samples while having somatic mutations in two of
our PN patients.

#### 240 Somatic copy number variation in PN

241 In addition to somatic SNVs and indels, somatic copy-number variation (CNV) may contribute to the phenotype of PN phenotype by altering gene dosage. Copy number analysis of 242 243 exome data identified a median of 66 somatic CNVs per PN patient (range of 48 to 344), 244 including characteristic recurrent deletions in chromosome 1p13 (6/17; 35%), 4p (5/17; 29%), 245 4q13.2 (4/17; 24%), 5q (3/17; 18%), 7q21 (3/17; 18%), 11q14 (5/17; 29%), 12 (7/17; 41%), and 246 19q13.42 (4/17; 24%). Since the method we used gives a greater weight to high amplitude 247 events that are less likely to occur by chance, we also identified significant gains in 248 chromosome 7p22 and chromosome 17g25.3 in one sample (P < 0.05; see Methods). We noted 249 distinct patterns of recurrent somatic CNV in PN by race: Caucasian patients more commonly 250 had deletions in chromosome 1p13.3 (4/5; 80%) and duplications in chromosome 15 (3/5; 60%). 251 whereas African American patients more commonly had deletions involving chromosome 4p 252 (5/12; 42%), 4q13.2 (4/12; 33%), 7q21 (3/12; 25%), 11q14 (5/12; 42%), and 12 (5/12; 42%) 253 (Figure 4A-C). Overall, recurrent somatic deletions had an overlap with 3173 gene loci and 254 somatic duplications overlapped with 5 gene loci: FOXK2, WDR45B, EIF3B, RSPH10B2, and 255 CCZ1B. 256 Previous studies show that CNV affects gene expression and biological processes (52,

53). To investigate the functional impact of somatic CNV in PN, we overlapped genes affected
by recurrent somatic CNV calls in our PN cohort with genes found to be differentially expressed
in PN lesional skin using RNA-seq data (10). We identified 264 genes that were significantly

It is made available under a CC-BY-NC-ND 4.0 International license .

260	downregulated (FDR-adjusted $P < 0.05$ ; log fold-change < 0) as well as recurrently deleted in
261	PN lesional skin. Enrichment analysis of those 264 genes showed that the deleteriously affected
262	pathways were most significantly related to neural crest cell development, negative regulation of
263	chemotaxis, and negative regulation of axonal extension (Figure 4E). Manual review of the
264	enrichment results revealed that it was primarily driven by a recurrent 7q21 deletion affecting
265	SEMA3C, SEMA3E, SEMA3A, and SEMA3D (Figure 4D). There were two gene loci that
266	overlapped recurrently duplicated segments and were significantly upregulated in PN lesional
267	skin: FOXK2 and EIF3B.

268 Since not all of the RNA-seg samples we used overlapped with the WES samples, and 269 to demonstrate that the enrichment in neurotropic pathways is driven by somatic deletions, we 270 repeated the enrichment analysis using expression data only as a negative comparator-there was no significant enrichment in those neuronal pathways without CNV information (Figure S2). 271

- 272 We then performed CNV signature analysis to investigate the common etiology, if any, of 273 such wide-scale somatic events. We identified 3 CNV signatures in our samples based on loss-274 of-heterozygosity status, total copy number state, and segment length. One CNV signature was 275 highly similar to known signature CN12 from the COSMIC curated database (0.837 cosine 276 similarity), which is believed to be a focal loss-of-heterozygosity signature indicating 277 chromosomal instability in association with a enome doubling event (54). African American and 278 Caucasian patients displayed similar exposure to CN12 (P = 0.58, Fisher's exact test) (Figure 279 4F-G).
- 280

# Somatic mutational landscape of PN compared to AD

281 Distinct somatic mutational landscape in PN. Somatic mutational analysis of AD lesional 282 skin revealed a median of 75 lesion-specific mutations per patient (range of 37 to 1161), with 283 the highest frequency of recurrent nonsynonymous somatic mutations in TTN (4/9: 44%). 284 DNHD1 (3/9; 33%), USP20 (3/9; 33%), and ANKRD36 (3/9; 33%) (Figure 5 A). Of note, none of

It is made available under a CC-BY-NC-ND 4.0 International license .

the AD samples had somatic mutations in *NOTCH1* (Figure 5D). Somatic mutations in AD lesional skin had a median mutational burden of 0.66 per megabase (range of 0.28 to 92.7) and median VAF of 0.04 (range of 0.010 to 0.405), which were significantly higher than those of PN (P < 0.001, Wilcoxon) (Figure 5B and E).

To investigate the somatic mutational landscape more characteristic of PN compared to AD, we started with the set of 46 genes that had nonsynonymous mutations in at least two PN patients and filtered those genes that had any nonsynonymous mutations in our AD cohort. This analysis yielded 21 genes for PN. We performed enrichment analysis on the resulting gene list. The most significant pathways were related to the Notch-mediated HES/HEY network, E2F transcription factor network, microtubule cytoskeleton, neuron migration, and others (Figure 5F and G).

We found a nonsense mutation (p.Trp1374Ter) and two missense mutations (p.Glu1017Gly, p.Ser1067Leu) across two AD patients in *DUOX2*. Notably, the same nonsense mutation in *DUOX2* appeared in one PN sample and this is the only recurrent nonsense mutation we observed across both conditions. *DUOX2* is primarily responsible for the release of hydrogen peroxide through NADPH oxidase and variant protein products have been associated with elevated plasma IL17C levels (55, 56).

Mutational signatures. Analysis of the mutational processes in PN and AD lesional skin 302 identified the presence of 4 single-nucleotide substitution (SBS) and 2 double-nucleotide 303 304 substitution signatures (DBS). SBS signatures were most similar to SBS7b (UV exposure; 305 similarity: 0.966), SBS6 (DNA mismatch repair; similarity: 0.806), and SBS5 (unknown etiology, 306 similarity: 0.781), from the COSMIC database (57) (Figure 5A). SBS5 has unknown etiology but it is found to have increased burden in many cancer types and is clock-like in that its exposure 307 308 correlates with the age of the individual (57). We also detected a de-novo SBS signature in AD 309 and PN characterized by frequent A[T>]G and G[C>T]C substitutions. SBS signatures had

It is made available under a CC-BY-NC-ND 4.0 International license .

310 similar distribution across PN and AD groups. DBS signatures only correlated with DBS1 (UV 311 exposure; similarity: 0.999), characterized by transcriptional bias with more CC>TT substitutions. We also identified a de-novo DBS signature characterized by frequent TG>CA 312 313 substitutions. For each detected mutational signature, a multiple linear regression model was built to test if age, sex, PN diagnosis (compared to AD diagnosis), and itch intensity significantly 314 predicted the corresponding signature's exposure. The regression model of DBS1 was 315 statistically significant (goodness-of-fit adjusted  $R^2 = 0.66$ , P = 0.004). DBS1 was significantly 316 317 associated with PN diagnosis ( $\beta = 0.779$ , P < 0.001) and itch intensity ( $\beta = 0.187$ , P = 0.003). 318 Immunofluorescence analysis. Our somatic analyses identified NOTCH1 as the most 319 frequently mutated gene in PN lesional skin. As functional validation, we performed 320 immunofluorescent (IF) staining of four lesional and four matching nonlesional PN samples confirmed to have mutations in NOTCH1. Representative skin section images are shown in 321 322 Figure 7A. Intensive staining for the notch intracellular domain (NICD), an indicator of active 323 Notch signaling, was observed in both lesional and nonlesional skin of PN patients. However, 324 NICD showed significantly higher expression in lesional dermis compared to nonlesional dermis from the same PN patients (t(3) = 5.92, P = 0.010, paired Student's t-test). There was no 325 significant difference in NICD expression between lesional and nonlesional PN epidermis (t(3) = 326 327 -0.226, P = 0.836) (Figure 7B and C). PN lesional skin had significantly higher co-localization of 328 Notch1 with vimentin, a relatively specific marker for fibroblasts, compared to nonlesional skin of the same patients (t(3) = 4.77, P = 0.018) (Fig 7 D & E). While NOTCH1 also co-localized with 329 330 KRT10, a keratinocyte marker, there was no significant difference in co-localization between 331 lesional and nonlesional PN skin (t(3) = -2.09), P = 0.128) (Figure S2). 332 Multi-center analysis. To test and demonstrate the clinical relevance of our findings for 333 PN patients, we first identified the top 10 non-congenital, nonredundant diseases with the

highest evidence for *NOTCH1* involvement, as determined by the gene-disease association

It is made available under a CC-BY-NC-ND 4.0 International license .

335	(GDA) score from DisGeNET (58). Highest GDAs included aortic valve calcification (0.65),					
336	precursor T-cell lymphoblastic leukemia/lymphoma (0.6), and head and neck SCC (0.6). We					
337	then leveraged a mult-center cohort through the TriNetX Research Network. 42,397 PN patients					
338	without a history of any neoplasms were identified. Controls were identified through 1:1					
339	propensity-score matching based on age, sex, race, ethnicity, smoking status, and history of					
340	hypertension (Figure 8A; Table S3). Compared to matched controls, PN patients had a higher					
341	relative risk (RR, [95% confidence interval]) of precursor T-cell lymphoblastic					
342	leukemia/lymphoma (5.33, [2.88 to 9.88]), head and neck SCC (4.19, [3.22, 5.45]), cervical					
343	cancer (3.00, [1.85 to 4.80]), breast cancer (2.91, [2.50, 3.40]), bladder cancer (2.83, [1.924,					
344	4.158]), connective tissue disease (2.48, [2.15, 2.87]), aortic valve calcification (1.96, [1.78,					
345	2.18]), and aortic aneurysm (1.93, [1.680, 2.219]) (Figure 8B). There was no significant					
346	increased risk for adenoid cystic carcinoma or glioblastoma in PN patients.					
347	Discussion					
348	This is the first study to our knowledge to comprehensively investigate somatic					
349	mutational events in PN, and we identified recurrent nonsynonymous somatic mutations in PN					
350	lesional skin related to the Notch pathway. Increased Notch signaling was observed in PN					
351	lesional dermis, along with increased NOTCH1 expression in fibroblasts from PN lesional skin.					
352	PN patients were also found to be at an increased risk of several NOTCH1-associated					
353	conditions compared to matched controls. Additional findings related to PN biology include					
354	downregulated and somatically deleted genes in PN lesional skin associated with neuronal					
355	pathways, driven by a 7q21 deletion only seen in African American PN patients. Finally, PN					
356	patients had significantly more UV-associated mutational signatures compared to AD patients,					

358 Our findings highlight a role for Notch signaling in PN pathology. The Notch intracellular 359 pathway is highly conserved and plays key roles in specifying cell fates during normal tissue

It is made available under a CC-BY-NC-ND 4.0 International license .

360 development and homeostasis (59). Abnormal Notch signaling has been implicated in various 361 human diseases and neoplasms (60). Our study identifies NOTCH1 as the gene with most 362 frequent nonsynonymous somatic mutations in PN. Enrichment analysis revealed that 363 recurrently mutated genes in PN were significantly related to the Notch-mediated HES/HEY 364 network, even after filtering genes mutated in AD controls. NOTCH1 mutations have been 365 strongly associated with multiple malignancies, including cSCC-a recent metanalysis of 83 366 cSCCs using multiple cancer gene discovery methods found NOTCH1 as the top driver gene of 367 cSCC (47). In the present study, NOTCH1 was the most recurrently mutated gene in PN, and 368 NOTCH1 mutations significantly co-occurred with NCOA1 mutations of the same oncogenic 369 pathway, suggesting a proliferative attribute to PN lesional skin. Our comparison between PN 370 and cSCC somatic data also identified FAT1 as a recurrently mutated gene in our PN samples, 371 another high-confidence driver of cSCC. PN patients are more likely than the general population 372 to have coexisting health conditions, including malignancies (1, 61). In particular, we previously 373 found PN patients at increased risk of developing SCC (25). The present study also found an 374 association between PN and several malignancies using a multi-center cohort, and further found 375 new associations between PN and NOTCH1-associated conditions. 376 In addition to its role in cellular proliferation, Notch signaling also has established roles in 377 tissue fibrosis in several diseases, including renal, hepatic, pulmonary, and myocardial fibrosis 378 (62–65). The profibrotic effect of Notch1 is likely a function of fibroblast proliferation,

myofibroblast differentiation, and immune dysregulation through TGF- $\beta$  signaling (30, 66, 67).

380 Activation of Notch signaling was observed in the lesional skin of patients with systemic

- 381 sclerosis, and stimulation of healthy dermal fibroblasts with a Notch1 ligand resulted in a
- 382 phenotype similar to that of systemic sclerosis with increased release of collagen and
- differentiation of resting fibroblasts into myofibroblasts (68). Interestingly, these findings are

It is made available under a CC-BY-NC-ND 4.0 International license .

aligned with single-cell RNA sequencing studies indicating increased myofibroblasts in PN
 lesional skin (14).

386 Given its immunomodulating properties, hyperactive Notch signaling further contributes 387 to fibrosis by inducing an M2 to M1 (proinflammatory) macrophage polarization, leading to myofibroblasts proliferation and recruitment of fibrocytes (69). The transition between M2 and 388 389 M1 macrophages is also induced by IL-31 (70), which helps connect Notch dysregulation, 390 inflammatory cytokine release, and itch propagation to tissue fibrosis (71, 72). Further, 391 transcriptomic analysis of liver cancer hepatocytes shows a correlation in NOTCH1 expression 392 and POSTN, which encodes periostin (73). Periostin, an extracellular matrix protein released by 393 skin fibroblasts, is found in the dermis of patients with PN at levels that correlate with itch 394 intensity (74). Recent single-cell studies in PN showed significantly increased periostin in 395 lesional skin and supports a fibroblast-neuronal axis in PN regulated by periostin (14). 396 Hyperactivation of a compromised Notch1 receptor may be one possible mechanism by which 397 somatic mutations in NOTCH1 lead to the clinical cutaneous fibrosis observed in PN lesional 398 skin. IF analysis demonstrated both significantly increased Notch signaling in lesional PN 399 dermis and increased expression of NOTCH1 in lesional PN skin fibroblasts. Due to its 400 profibrotic and proinflammatory roles, and its relatively high mutation rate and activation in PN 401 lesional skin, our study identifies NOTCH1 as a driver in PN biology and Notch signaling as a 402 putative target for therapeutics (60).

This study also finds significant somatic mutations in neuronal pathways. Notch1 is known to inhibit neurite outgrowth in neurons, and inhibition of hyperactive Notch signaling can reverse neurogenesis and neurite outgrowth defects (75, 76). We also observed recurrent nonsynonymous mutations in genes related to neuron projection including *MAP1B*, *TENM1*, and *CNTN2*, which were not mutated in AD. Those genes were also found to be significantly downregulated in PN lesional skin compared to nonlesional skin (10), suggesting the mutations

It is made available under a CC-BY-NC-ND 4.0 International license .

lead to altered neuronal structure in PN lesional skin. Further, analysis of somatic CNV in PN
 reveals that recurrently deleted segments affect genes which are most significantly related to
 neural crest development and negative regulation of axon extension.

Previous functional studies on lesional and nonlesional PN skin biopsies show altered
intraepidermal and dermal nerve fiber density (77). Our mutational profiles suggest primary
neuronal gene dysregulation in PN lesional skin. This is supported by association studies
showing a correlation between a PN diagnosis and other systemic neuropathies (78).

416 Following our somatic CNV analysis, enrichment in axonal growth and guidance was 417 largely due to a recurrent 7g21 deletion that overlaps with SEMA3A and related genes of the 418 Semaphorin-plexin signaling pathway. This deletion was only observed in African American 419 patients. This is notable in light of the disproportionate burden of PN in skin of color patients, 420 with African Americans having a 3.4 to 4.4 times increased odds of developing PN compared to 421 Whites (26, 61). In addition to CNV differences, we also observed unique high-VAF mutations 422 affecting epithelial-to-mesenchymal transition African American PN patients, suggesting a 423 distinct somatic evolutionary landscape in those patients. This is remarkable given that African Americans with PN often present much differently than Caucasian patients with more fibrotic 424 425 lesions (Figure 1B and C). Previous transcriptomic studies suggest unique patterns of immune 426 polarization in African American patients with PN (15). Somatic CNV analysis in this study adds 427 further molecular foundation for the high rate of PN in African Americans and suggests a novel 428 disease endotype may exist in these patients.

We observed other mutations that suggest a branch of common etiology between PN and AD. The only recurrent nonsense mutation in PN and AD was in *DUOX2*, which is involved in the release of hydrogen peroxide through NADPH oxidase (55). *DUOX2* is highly sensitive to mutation, and altered protein products have been associated with elevated plasma IL17C levels, which is characteristic of the inflammatory profiles of AD and psoriasis (55). Transcriptional and

It is made available under a CC-BY-NC-ND 4.0 International license .

434 functional studies show elevated Th17 signatures in PN patients as well, both in the skin and systemically (10, 79). However, the difference in PN is that its immunophenotype is more likely 435 436 an imbalance between Th17 and Th22, with elevated levels of IL-22 (10). Interestingly, Notch 437 signaling is shown to promote IL-22 secretion and the skewing of naïve CD4<sup>+</sup>T cells toward 438 Th22 cells (80). Further, Notch1 inhibition was shown to effectively alleviate the severity of psoriasis-like skin inflammation by regulating Th17 differentiation and function (81). Hyperactive 439 440 Notch1 signaling can also destabilize regulatory T cells (82, 83), leaving way for unrestrained Th2-driven inflammation and itch (84). The Notch pathway was found highly mutated and 441 442 hyperactive in PN lesional in this study, providing support and a genomic context to the Th17/Th22-skewed immunologic signature of PN. This is an area where precision therapeutics 443 444 will make an impact, as each PN patient's treatment can be informed by their immunologic or 445 genomic signature.

446 To investigate the etiology of somatic mutational processes we observed, we performed 447 mutational signature analysis in PN and compared it to that of AD. The relative frequency of 448 DBS1, a highly specific signature for UV exposure with frequent tandem CC>TT mutations, was 449 significantly associated with PN. This was after controlling for age, race, and itch intensity. 450 DBS1 significantly correlated with itch intensity in both conditions. NOTCH1 is one of the most 451 highly mutated genes in sun-exposed versus non-sun-exposed normal human skin samples 452 (85), and chronic UV-A exposure was shown to expand dermal fibroblasts harboring NOTCH1 453 amplifications (86). Subacute skin-barrier damage maybe an early-event in PN patients that 454 increases susceptibility to UV-induced DNA damage, paving the way for accumulated somatic 455 mutations and exacerbating dysregulation in the skin microenvironment. Interestingly, we did 456 not find DBS1 associated with age. Previous work shows a similar pattern in skin fibroblasts 457 where UV-associated DNA damage did not correlate with age, suggesting a proliferative origin 458 (87).

It is made available under a CC-BY-NC-ND 4.0 International license .

459	We recognize some limitations in our study. First, we only sequenced samples from 17
460	PN cases and 10 AD controls, although PN is a relatively rare condition (61). Thus, we may
461	have missed somatic events relevant to PN in a subset of patients. In addition, CNV analysis
462	using WES data is limited in scope and cannot delineate all complex somatic structural
463	variations. Nonetheless, our study represents the first and largest genomic sequencing effort for
464	a rare and understudied disease. Our characterization of the somatic landscape in PN reveals
465	novel insights into its pathology. Aberrant Notch signaling is identified as a likely driver in PN
466	development, likely through profibrotic and immune deregulatory functions, with potential
467	systemic involvement. We also provide support for the neuronal dysregulation pathophysiology
468	of PN through identifying recurrent loss-of-function mutations in MAP1B, TENM1, and CNTN2,
469	as well as recurrent copy number deletions supported by gene expression data. Finally, our
470	mutational signature analysis revealed a strong association between DBS1 and PN, suggesting
471	a potential role for UV-exposure in PN development or maintenance. Our findings represent
472	much needed progress to profile PN on the molecular level.

473 Methods

474 Sample collection. Patients diagnosed with moderate-to-severe PN, with more than 20 nodules 475 and a Worst-Itch Numeric Rating Scale (WINRS) score (88) of more than 7 out of 10 were recruited from the Johns Hopkins Itch Center. For AD controls, patients diagnosed with 476 moderate-to-severe AD with a validated Investigator Global Assessment (vIGA) score (89) of 477 478 greater than or equal to 3 and a WINRS score of more than 7 out of 10 were recruited from the 479 Johns Hopkins Itch Center. 6-mm punch biopsies from lesional PN or AD skin and healthy, 480 nonlesional skin within 10 cm of the nodule were collected. Half of each biopsy was formalinfixed, paraffin-embedded (FFPE) and the other half was stored in RNALater solution (Ambion). 481 482 All patients signed a consent form approved by the local Institutional Review Board.

It is made available under a CC-BY-NC-ND 4.0 International license .

483 Whole-exome analysis. Library preparation was performed with the SureSelectXT reagent kit 484 before hybridization. SureSelect XT Human All Exon V5 library was used for hybridization. 485 NovaSeq6000 S4 was used for sequencing 150 bp paired-end reads. Illumina's CASAVA 486 (v1.8.4) was used to convert BCL files to FASTQ files. Initial guality control was performed using 487 FastQC (v0.11.8). Trimgalore (v0.6.7) (90) was used to trim adapters, low-quality base calls, and short reads using default parameters. Following the "Best Practices" workflow suggested by 488 489 the Broad Institute, BWA-mem (v0.7.17) (91) was used for alignment against the hg38 reference denome. Piccard-tools (v2.9.0) were used to mark duplicate reads. GATK (v3.8.0) 490 491 IndelRealigner (92) was used to clean indel artifacts, and GATK BaseRecalibrator was used to 492 recalibrate base quality scores and improve downstream variant calling. Samtools (v1.10) (93) 493 and GATK were used to determine coverage at different levels of partitioning and aggregation. 494 One AD sample was excluded due to low coverage (see Results). GATK MuTect2 was used to 495 call somatic. To focus on somatic events relevant to the development of a prurigo nodule, and to 496 further reduce the likelihood of germline calls, MuTect2 paired mode was used with lesional and nonlesional samples as the "tumor" and normal samples, respectively. The default parameters 497 498 were used. Common germline variants and artifacts were filtered using a panel of normal 499 exomes from the ExAC database; variants present in 2 or more samples within the panel of 500 normals were removed. Somatic variants were then filtered using the following criteria: minimum 501 phred quality of 20, minimum read depth of 20, and minimum variant allele frequency of 0.01. 502 The functional effects of passed somatic SNVs and indels were then predicted using SnpEff 503 (v5.0) (94). The R package Maftools (v2.21.05) (95) was used to summarize and visualize 504 variant calls.

After variant calling, we considered excluding a hypermutated AD sample with 34,228 detected somatic variants after filtration. The rest of the AD samples had a median of 83.5 variants (range of 48 to 578). While this high number of variants might represent significant

It is made available under a CC-BY-NC-ND 4.0 International license .

underlying germline variation or technical artifacts, it may also reflect true hypermutation related
to AD. Since this study did not focus on investigating AD pathology, and the AD variants were
rather primarily used to curate a gene list that is more likely to be specific to PN somatic
mutagenesis, the hypermutated AD sample was not excluded.

512 *Gene set enrichment analysis*. Enrichr (96) was used to perform gene set enrichment analysis 513 using the following term databases: GO Biological Process, GO Cellular Component, and NCI 514 Nature Pathways. Significant GO terms and pathways were calculated using an alpha level of 515 0.05 after applying the Benjamini–Hochberg correction and output was visualized in R.

516 Copy number analysis. Somatic CNV was inferred using CNVkit (v0.9.4) (97), using baited

517 genomic regions for the whole-exome target capture kit S04380110 (i.e. SureSelect Human All

518 Exon V5). Nonlesional samples were combined into a pooled reference for CNV calling, as

519 opposed to an individual-matched analysis, which is the recommendation of the CNVkit authors

520 for reduced CNV noise. Significantly recurrent CNV segments were identified using CNVRanger

521 (98), which implements the statistical approach described by Beroukhim et al. to highlight

regions that are aberrant more often than would be expected by chance, with greater weight

assigned to high-amplitude events (homozygous deletions or high-level copy-number gains)

524 (99).

525 *RNA-seq data.* In order to corroborate and contextualize the functional impact of somatic CNV

526 calls, we utilized in-house gene expression data from lesional and non-lesional PN samples.

527 Differential expression pipeline is described previously (100). Briefly, normalization and

528 differential expression of RNA-seq data was carried out using the DESeq2 (101) R package,

- 529 with adjustment for multiple hypothesis testing using Benjamini-Hochberg. Genes with adjusted-
- 530 *P* less than 0.05 and  $\log_2$  fold-change change < 0 or > 0 were considered down- and

<sup>531</sup> upregulated, respectively. A relatively permissive absolute fold-change cutoff was used to allow

532 enrichment to be driven by somatic CNVs.

Rajeh et al.

It is made available under a CC-BY-NC-ND 4.0 International license .

533	Mutational signature analysis. Mutational signatures for the landscape of single nucleotide
534	substitution (SBS), double nucleotide substitution (DBS), and CNV across exomes were
535	extracted based on the non-negative matrix factorization method previously described and
536	implemented in the Sigminer R package (v2.1.7) (102, 103). CNV signatures were classified as
537	recently described by Steele et al.; in brief, to capture biologically relevant copy number
538	features, a CNV signature encodes the copy number profile of a sample by summing the counts
539	of segments into a 48-dimensional vector based on total copy number, heterozygosity status,
540	and segment size (54). The optimal number of mutational signatures to extract was determined
541	by inspecting the cophenetic correlation coefficient, an indicator of the robustness of consensus
542	matrix clustering, and choosing the minimal number of signatures after which the coefficient
543	starts sharply decreasing (104). Signatures were then compared with the curated set of
544	COSMIC signatures v3.3 (57) using cosine similarity. Signatures with less than 0.7 similarity to
545	any known signatures in COSMIC were considered de-novo.
546	Mutational burden. We calculated mutational burden as the number of nonsynonymous

547 mutations occurring per megabase of coding regions.

548 Shannon Diversity Index for somatic mutations. Variant-allele frequency (VAF; *v*) was inferred 549 as the number of reads supporting the variant allele, SNV or indel, divided by the total reads 550 supporting the reference allele and the reads supporting the variant allele. Assuming we 551 sequenced n sites, the Shannon Diversity Index, H, for a sample was then calculated as:

552 
$$\mathbf{H} = -\sum_{i=1}^{n} v_i \ln \mathbf{h}$$

*Immunofluorescence analysis.* We selected four PN patients whom we found to have *NOTCH1*mutations. Lesional and nonlesional FFPE skin samples of 5-µm thickness were deparaffinized
and subjected to heat-induced antigen retrieval using Trilogy buffer (Trilogy® 920P x1, SigmaAldrich) and treated with DAKO protein blocking reagent (X0909, DAKO, Capinteria, CA, USA).
The slides were then incubated with primary antibodies for Notch1 (ab52627, Abcam, 1:150)

 $v_i$ 

It is made available under a CC-BY-NC-ND 4.0 International license .

558 and human NICD (AF3647, R&D Systems; dilution, 1:20) at 4°C overnight, followed by reaction with conjugated secondary antibodies, DAPI intranuclear stain (62248, Thermofisher Scientific) 559 560 and mounted with ProLong Glass Antifade Mountant (P36980, Thermofisher Scientific). For 561 quantification, photomicrographs were obtained with Leica SP8 confocal microscope (Leica 562 Microsystems, Deerfield, IL, USA) at 20x objective and x63 objective oil immersion using 563 instrument settings. Background normalized fluorescence intensity of the antibodies in the 564 epidermis and dermis was measured in arbitrary units (AU) using Image J software (NIH, 565 Bethesda, MD, USA).

566 Gene-disease associations. We used DisGeNET (v7.0) (58) to identify diseases associated with 567 NOTCH1. At the time of the study, DisGeNET had 1,134,942 gene-disease associations 568 (GDAs) between 21.671 genes and 30.170 diseases. Their methodology ranks diseases based on a GDA score which gives a higher weight to associations reported by several expert-curated 569 570 databases and with a large number of supporting publications (58). We excluded congenital 571 conditions (e.g., bicuspid aortic valve) and redundant terms (e.g., malignant neoplasm and 572 breast neoplasm: only breast neoplasm was included). The 10 remaining diseases with the 573 highest GDA were then selected as a priori primary outcomes in our PN cohort study. 574 Cohort study. The TriNetX Research Network is an international, federated clinical database 575 which contains approximately 107 million patient records at the time of this study. We first identified patients with a diagnosis of PN without any previous history of neoplasms before PN 576 diagnosis. We utilized the International Classification of Diseases 10<sup>th</sup> Revision Clinical 577 578 Modification (ICD-10-CM) code L28.1, which is given mostly by dermatologists and has been 579 validated (105). Controls were identified through 1:1 propensity-score matching based on age, 580 sex, race, ethnicity, smoking status, and history of hypertension. Primary outcomes were 581 determined through corresponding ICD-10-CM codes and association was determined through

It is made available under a CC-BY-NC-ND 4.0 International license .

- cumulative relative risk estimated using the TriNetX analytics web platform. All TriNetX analyses
   were completed on 02/10/2023.
- 584 Statistics. Statistical tests and visualizations were performed using R (version 4.2.0).
- 585 Adjustment for false-discovery rate (FDR) due to multiple hypothesis testing was conducted
- using the Benjamini–Hochberg method. An alpha level of 0.05 was used to denote significance.
- 587 Study approval. This study was approved by the Johns Hopkins Institutional Review Board
   588 (IRB00231694).

# 589 Acknowledgements

- 590 S.G.K. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases
- of the National Institutes of Health under Award Number K23AR077073 and a grant from the
- 592 Skin of Color Society. The content is solely the responsibility of the authors and does not
- 593 necessarily represent the official views of the National Institutes of Health. We thank the Sidney
- 594 Kimmel Comprehensive Cancer Center Experimental and Computational Genomics Core,
- receiving support through NCI grant P30CA006973, for assistance with the WES next
- 596 generation sequencing studies and analysis. We also thank the PN and AD patients who
- 597 donated tissue samples for this study.
- 598 Author contributions

manuscript.

- 599 SGK, SY, AG, YRS, MMK, TP, and AR designed the study. VP, JD, HC, AK, and SVR collected
- 600 the data. AR, AG, MDS, and SW analyzed the data. HC, AK, and OO performed staining. AR
- and SGK wrote the first version of the manuscript. All authors reviewed and edited the
- 602
- 603

# 604 **References**

1. Kwatra SG. Breaking the Itch–Scratch Cycle in Prurigo Nodularis. *N Engl J Med*. 2020;382(8):757–758.

Rajeh et al.

- 606 2. Kwatra SG. Prurigo Nodularis. *JAMA Dermatol*. 2022;158(3):336.
- 607 3. Steinke S, et al. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses:
- 608 Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity
- and Burden of Pruritus (PruNet) cross-sectional trial. J Am Acad Dermatol. 2018;79(3):457-463.e5.
- 610 4. Whang KA, et al. Health-related quality of life and economic burden of prurigo nodularis. *J Am Acad*
- 611 *Dermatol.* 2022;86(3):573–580.
- 5. Aggarwal P, et al. Clinical characteristics and disease burden in prurigo nodularis. *Clin Exp Dermatol*.
- 613 2021;46(7):1277–1284.
- 614 6. Whang KA, et al. Racial and Gender Differences in the Presentation of Pruritus. *Medicines*.
- 615 2019;6(4):98.
- 616 7. McColl M, et al. Pruritus in Black Skin: Unique Molecular Characteristics and Clinical Features. J Natl
- 617 *Med Assoc*. 2021;113(1):30–38.
- 618 8. Sutaria N, et al. Racial disparities in mortality among patients with prurigo nodularis: A multi-center
- 619 cohort study. *J Am Acad Dermatol*. 2022;86(2):487–490.
- 620 9. Wongvibulsin S, et al. A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare
- 621 Utilization in the United States. *J Invest Dermatol*. 2021;141(10):2530-2533.e1.
- 622 10. Belzberg M, et al. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune
- 623 Polarization. *J Invest Dermatol*. 2021;141(9):2208-2218.e14.

It is made available under a CC-BY-NC-ND 4.0 International license .

624	11. Sutaria N, et al. Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene
625	Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis. J Invest Dermatol.
626	2022;142(9):2537–2540.

- 627 12. Parthasarathy V, et al. Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory
- biomarkers in prurigo nodularis: A cluster analysis. *Front Med*. 2022;9.
- https://www.frontiersin.org/articles/10.3389/fmed.2022.1011142. Accessed February 20, 2023.
- 630 13. Deng J, et al. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis

631 compared to atopic dermatitis. *Front Med*. 2022;9:1022889.

- 632 14. Patel JR, et al. Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo
- 633 nodularis [preprint]. 2023;2023.01.29.526050.
- 634 15. Sutaria N, et al. Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a
- 635 Distinct Systemic Inflammatory Signature in African Americans. J Invest Dermatol. 2022;142(5):1300-

636 1308.e3.

- 637 16. Parthasarathy V, et al. The blood proteomic signature of prurigo nodularis (PN) reveals distinct
- 638 inflammatory and neuropathic endotypes: a cluster analysis. J Am Acad Dermatol. 2023;0(0).
- 639 https://doi.org/10.1016/j.jaad.2023.01.042.
- 640 17. Vasavda C, et al. A polygenic risk score for predicting racial and genetic susceptibility to prurigo
  641 nodularis. *J Invest Dermatol.* 2023.
- 642 18. Brown SJ. Molecular mechanisms in atopic eczema: insights gained from genetic studies. *J Pathol*.
  643 2017;241(2):140–145.

- 644 19. Zhou X, et al. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin
- 645 Treatment Difference. *Int J Mol Sci.* 2017;18(2):295.
- 646 20. Olafsson S, Anderson CA. Somatic mutations provide important and unique insights into the biology
- 647 of complex diseases. *Trends Genet*. 2021;37(10):872–881.
- 648 21. Martincorena I, et al. High burden and pervasive positive selection of somatic mutations in normal
- 649 human skin. *Science*. 2015;348(6237):880–886.
- 650 22. Klonowska K, et al. Ultrasensitive profiling of UV-induced mutations identifies thousands of
- 651 subclinical facial tumors in tuberous sclerosis complex. *J Clin Invest*. 2022;132(10).
- 652 https://doi.org/10.1172/JCl155858.
- 653 23. Olafsson S, et al. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of
- 654 the skin [preprint]. 2022;2022.07.04.22277086.
- 24. Nanki K, et al. Somatic inflammatory gene mutations in human ulcerative colitis epithelium. *Nature*.
  2020;577(7789):254–259.
- 657 25. Larson VA, et al. Association between prurigo nodularis and malignancy in middle-aged adults. *J Am* 658 *Acad Dermatol.* 2019;81(5):1198–1201.
- 659 26. Boozalis E, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. *J Am Acad*660 *Dermatol.* 2018;79(4):714-719.e3.
- 661 27. Koboldt DC. Best practices for variant calling in clinical sequencing. *Genome Med*. 2020;12(1):91.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 662 28. Gu C, et al. Identification of Common Genes and Pathways in Eight Fibrosis Diseases. *Front Genet*.
- 663 2021;11. https://www.frontiersin.org/articles/10.3389/fgene.2020.627396. Accessed September 10,
- 664 2022.
- 665 29. Sondka Z, et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human
- 666 cancers. *Nat Rev Cancer*. 2018;18(11):696–705.
- 667 30. Condorelli AG, et al. Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the 668 multifaceted Notch signalling pathway. *J Biomed Sci*. 2021;28(1):36.
- 669 31. Fukusumi T, Califano JA. The NOTCH Pathway in Head and Neck Squamous Cell Carcinoma. *J Dent*

670 *Res.* 2018;97(6):645–653.

- 32. Sakamoto K, et al. Distinct roles of EGF repeats for the Notch signaling system. *Exp Cell Res*.
  2005;302(2):281–291.
- 673 33. Remme CA. Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological,
- 674 molecular and genetic aspects. *J Physiol*. 2013;591(Pt 17):4099–4116.
- 34. Zhang Y, et al. Nav1.8 in keratinocytes contributes to ROS-mediated inflammation in inflammatory
  skin diseases. *Redox Biol.* 2022;55:102427.
- 677 35. Shiratori-Hayashi M, et al. Astrocytic STAT3 activation and chronic itch require IP3R1/TRPC-
- 678 dependent Ca2+ signals in mice. J Allergy Clin Immunol. 2021;147(4):1341–1353.
- 679 36. Ma X-X, et al. PiT2 regulates neuronal outgrowth through interaction with microtubule-associated
  680 protein 1B. *Sci Rep.* 2017;7(1):17850.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 681 37. Verdonschot JAJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased
- fibrosis and long-term life-threatening arrhythmias. *Eur Heart J.* 2018;39(10):864–873.
- 683 38. Akinrinade O, Koskenvuo JW, Alastalo T-P. Prevalence of Titin Truncating Variants in General
- 684 Population. *PLoS ONE*. 2015;10(12):e0145284.
- 685 39. Wesley T, et al. The attributes of plakins in cancer and disease: perspectives on ovarian cancer
- 686 progression, chemoresistance and recurrence. *Cell Commun Signal*. 2021;19(1):55.
- 687 40. Szabo S, Wögenstein KL, Fuchs P. Functional and Genetic Analysis of Epiplakin in Epithelial Cells.
- 688 *Methods Enzymol.* 2016;569:261–285.
- 689 41. Peppino G, et al. Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets
- 690 for Therapy. Int J Mol Sci. 2021;22(5):2321.
- 691 42. Stogmann E, et al. Autosomal recessive cortical myoclonic tremor and epilepsy: association with a
- 692 mutation in the potassium channel associated gene CNTN2. *Brain J Neurol*. 2013;136(Pt 4):1155–1160.
- 43. White AN, et al. Genetic deletion of Rgs12 in mice affects serotonin transporter expression and
- function in vivo and ex vivo. *J Psychopharmacol Oxf Engl*. 2020;34(12):1393–1407.
- 695 44. Klimke W, et al. The National Center for Biotechnology Information's Protein Clusters Database.
- 696 *Nucleic Acids Res*. 2009;37(suppl\_1):D216–D223.
- 697 45. Cogné B, et al. Missense Variants in the Histone Acetyltransferase Complex Component Gene TRRAP
- 698 Cause Autism and Syndromic Intellectual Disability. *Am J Hum Genet*. 2019;104(3):530–541.
- 699 46. Wei X, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat Genet*.
- 700 2011;43(5):442-446.

Rajeh et al.

- 701 47. Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. *NPJ*
- 702 *Genomic Med.* 2021;6(1):61.
- 48. Sanchez-Vega F, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell.
- 704 2018;173(2):321-337.e10.
- 49. Reimand J, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA,
- 706 Cytoscape and EnrichmentMap. *Nat Protoc*. 2019;14(2):482–517.
- 50. Hedberg ML, et al. Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma. Int J Mol Sci.
- 708 2022;23(7):3478.
- 51. Su Al, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. *Proc Natl Acad*
- 710 Sci U S A. 2004;101(16):6062–6067.
- 52. Stranger BE, et al. Relative Impact of Nucleotide and Copy Number Variation on Gene Expression
- 712 Phenotypes. *Science*. 2007;315(5813):848–853.
- 53. Zhou C, et al. Integrated Analysis of Copy Number Variations and Gene Expression Profiling in
- Hepatocellular carcinoma. *Sci Rep*. 2017;7(1):10570.
- 54. Steele CD, et al. Signatures of copy number alterations in human cancer. *Nature*.
- 716 2022;606(7916):984–991.
- 55. Grasberger H, et al. DUOX2 variants associate with preclinical disturbances in microbiota-immune
- homeostasis and increased inflammatory bowel disease risk. *J Clin Invest*. 2021;131(9).
- 719 https://doi.org/10.1172/JCl141676.

720	56. Guttman-Yassky E, Krueger JG. IL-17C: A Unique Epithelial Cytokine with Potential for
721	Targeting across the Spectrum of Atopic Dermatitis and Psoriasis. J Invest Dermatol. 2018;138(7):1467-
722	1469.
723	57. Alexandrov LB, et al. The repertoire of mutational signatures in human cancer. Nature.
724	2020;578(7793):94–101.
725	58. Piñero J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids
726	Res. 2020;48(D1):D845–D855.
727	59. Shen W, Huang J, Wang Y. Biological Significance of NOTCH Signaling Strength. Front Cell Dev Biol.
728	2021;9. https://www.frontiersin.org/articles/10.3389/fcell.2021.652273. Accessed September 25, 2022.
729	60. Allen F, Maillard I. Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.
730	Front Cell Dev Biol. 2021;9. https://www.frontiersin.org/articles/10.3389/fcell.2021.649205. Accessed
731	September 8, 2022.
732	61. Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: Epidemiology and clinical features. J Am Acad
733	Dermatol. 2020;83(6):1559–1565.
734	62. Yang YM, et al. Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation
735	and liver fibrosis. Sci Transl Med. 2019;11(496):eaat9284.
736	63. Yu C, et al. Histone demethylase JMJD3 protects against renal fibrosis by suppressing TGF $eta$ and
737	Notch signaling and preserving PTEN expression. <i>Theranostics</i> . 2021;11(6):2706–2721.
738	64. Zhou Y, et al. Astragalus injection attenuates bleomycin-induced pulmonary fibrosis via down-
739	regulating Jagged1/Notch1 in lungs. <i>J Pharm Pharmacol</i> . 2016;68(3):389–396.

710		FCT  1   CD10 N _+_L1 C	analina Aula Duataata Aa	nalmat Canalia a Di	المعيد معالم محاجم منطو
740	bo illi erai		gnaling Axis Protects Ag	zainst Cardiac D	vstunction inrougn
/ 10	00. LU L, CUU				y si an culori i m o agri

- 741 Inhibition of Myocardial Fibrosis in Diabetic Mice. *Front Cell Dev Biol*. 2021;9:757068.
- 66. Ma S, et al. Survivin promotes rheumatoid arthritis fibroblast-like synoviocyte cell proliferation, and
- the expression of angiogenesis-related proteins by activating the NOTCH pathway. *Int J Rheum Dis.*
- 744 2021;24(7):922–929.
- 745 67. Wang Y-C, et al. Notch1 promotes the pericyte-myofibroblast transition in idiopathic pulmonary
- fibrosis through the PDGFR/ROCK1 signal pathway. *Exp Mol Med*. 2019;51(3):1–11.
- 747 68. Dees C, et al. Notch signalling regulates fibroblast activation and collagen release in systemic
- 748 sclerosis. Ann Rheum Dis. 2011;70(7):1304–1310.
- 749 69. Keewan E, Naser SA. Notch-1 Signaling Modulates Macrophage Polarization and Immune Defense
- against Mycobacterium avium paratuberculosis Infection in Inflammatory Diseases. *Microorganisms*.
- 751 2020;8(7):1006.
- 752 70. Kan T, et al. IL-31 induces antitumor immunity in breast carcinoma. *J Immunother Cancer*.
- 753 2020;8(2):e001010.
- 754 71. Ständer S, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. *N Engl J Med*.
  755 2020;382(8):706–716.
- 756 72. Deng J, et al. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to
- 757 Severe Prurigo Nodularis Treated With Nemolizumab. JAMA Dermatol. 2023;e232609.
- 758 73. Kongkavitoon P, et al. Regulation of periostin expression by Notch signaling in hepatocytes and liver
- cancer cell lines. *Biochem Biophys Res Commun*. 2018;506(3):739–745.

- 760 74. Hashimoto T, et al. Dermal Periostin: A New Player in Itch of Prurigo Nodularis. *Acta Derm Venereol*.
- 761 2021;101(1):adv00375.
- 762 75. Berezovska O, et al. Notch1 inhibits neurite outgrowth in postmitotic primary neurons.
- 763 *Neuroscience*. 1999;93(2):433–439.
- 764 76. Winanto, et al. Organoid cultures of MELAS neural cells reveal hyperactive Notch signaling that
- 765 impacts neurodevelopment. *Cell Death Dis.* 2020;11(3):1–8.
- 766 77. Schuhknecht B, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo
- nodularis skin as a potential sign of subclinical cutaneous neuropathy. *Br J Dermatol*. 2011;165(1):85–91.
- 768 78. Hughes J-DM, et al. Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy:
- Suggesting a Role for Neural Dysregulation in Pathogenesis. *Medicines*. 2020;7(1):4.
- 770 79. Wong L-S, et al. IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis. J
- 771 Invest Dermatol. 2020;140(3):702-706.e2.
- 80. Zeng C, et al. The NOTCH-HES-1 axis is involved in promoting Th22 cell differentiation. *Cell Mol Biol Lett*. 2021;26(1):7.
- 774 81. Ma L, et al. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse
- psoriasis-like skin inflammation. *J Transl Med*. 2018;16(1):59.
- 776 82. Benamar M, et al. The Notch1/CD22 signaling axis disrupts Treg function in SARS-CoV-2–associated
- 777 multisystem inflammatory syndrome in children. *J Clin Invest*. 2023;133(1).
- 778 https://doi.org/10.1172/JCl163235.

- 779 83. Rivas MN, Arditi M. Notch1 signaling impairs regulatory T cells during multisystem inflammatory
- 780 syndrome in children. *J Clin Invest*. 2023;133(1). https://doi.org/10.1172/JCl166016.
- 781 84. Singer BD, D'Alessio FR. Regulatory T cell Itch reins in Th2 inflammation. *Cell Mol Immunol*.
- 782 2014;11(2):126–128.
- 783 85. Wei L, et al. Ultradeep sequencing differentiates patterns of skin clonal mutations associated with
- sun-exposure status and skin cancer burden. *Sci Adv*. 2021;7(1):eabd7703.
- 785 86. Katarkar A, et al. NOTCH1 gene amplification promotes expansion of Cancer Associated Fibroblast
- populations in human skin. *Nat Commun*. 2020;11(1):5126.
- 787 87. Abyzov A, et al. One thousand somatic SNVs per skin fibroblast cell set baseline of mosaic mutational
- load with patterns that suggest proliferative origin. *Genome Res.* 2017;27(4):512–523.
- 789 88. Ständer S, et al. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J
- 790 *Eur Acad Dermatol Venereol JEADV*. 2022;36(4):573–581.
- 791 89. Simpson E, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The
- development and reliability testing of a novel clinical outcome measurement instrument for the severity
- of atopic dermatitis. *J Am Acad Dermatol*. 2020;83(3):839–846.
- 794 90. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
- 795 *EMBnet.journal*. 2011;17(1):10–12.
- 91. Fast and accurate short read alignment with Burrows–Wheeler transform | Bioinformatics | Oxford
  Academic [Internet]. https://academic.oup.com/bioinformatics/article/25/14/1754/225615. Accessed
  September 18, 2022.

- 799 92. McKenna A, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-
- generation DNA sequencing data. *Genome Res*. 2010;20(9):1297–1303.
- 801 93. Li H, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078–
- 802 2079.
- 803 94. Cingolani P, et al. A program for annotating and predicting the effects of single nucleotide
- polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w<sup>1118</sup>2; iso-2; iso-3. *Fly*
- 805 (Austin). 2012;6(2):80–92.
- 806 95. Mayakonda A, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer.
- 807 *Genome Res.* 2018;28(11):1747–1756.
- 808 96. Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.
   809 *Nucleic Acids Res.* 2016;44(Web Server issue):W90–W97.
- 810 97. Talevich E, et al. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted
- 811 DNA Sequencing. *PLOS Comput Biol*. 2016;12(4):e1004873.
- 812 98. da Silva V, et al. CNVRanger: association analysis of CNVs with gene expression and quantitative
- 813 phenotypes. *Bioinformatics*. 2020;36(3):972–973.
- 814 99. Beroukhim R, et al. Assessing the significance of chromosomal aberrations in cancer: Methodology
- and application to glioma. *Proc Natl Acad Sci.* 2007;104(50):20007–20012.
- 816 100. Belzberg M, et al. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22
- 817 Immune Polarization. *J Invest Dermatol*. 2021;141(9):2208-2218.e14.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 818 101. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data
- with DESeq2. *Genome Biol*. 2014;15(12):550.
- 820 102. Alexandrov LB, et al. Deciphering signatures of mutational processes operative in human cancer.
- 821 *Cell Rep.* 2013;3(1):246–259.
- 103. Wang S, et al. Sigflow: an automated and comprehensive pipeline for cancer genome mutational
- signature analysis. *Bioinformatics*. 2021;37(11):1590–1592.
- 824 104. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC
- 825 *Bioinformatics*. 2010;11(1):367.
- 826 105. Roh YS, et al. Validation of International Classification of Diseases Tenth Revision code for prurigo
- 827 nodularis. J Am Acad Dermatol. 2022;87(2):482–484.
- 828

It is made available under a CC-BY-NC-ND 4.0 International license .

830 Figure 1. Somatic mutational landscape of PN. (A) Schematic of the study design including sample collection and analysis. (B, C) Example skin images of two patients with prurigo nodularis (PN) enrolled in 831 832 this study. (B) Dorsal left arm of an African American patient with scattered prurigo nodules. (C) Right arm 833 of a Caucasian patient with scattered prurigo nodules. (D) Demographic information of PN and atopic 834 dermatitis (AD) patients. (E) Waterfall plot displaying somatic mutations in 15 of the most frequently 835 mutated genes in PN lesional skin compared to nonlesional skin. Ties were broken by known gene 836 function. Columns represent the 17 PN patients. Numbers shown on the right indicate the frequency of 837 gene mutation. Total nonsynonymous somatic SNPs and indels per sample are displayed on top. One 838 sample was hypermutated with 450 mutations. Bottom plot shows the frequency of different classes of 839 SNVs. Variants annotated as Multi Hit are those genes which mutated more than once in the same 840 sample. (F) Total number of somatic mutations per sample, broken down by predicted impact on protein 841 product based on snpEff, with functional (High or Moderate) impact in yellow and nonfunctional (Low or 842 Modifier) in blue. (G) Boxplot showing the variant allele frequency (VAF) of nonsynonymous somatic mutations across race. (H) \*\*, P < 0.01. 843

- 844
- 845
- 846
- 847

Figure 2. Distinct somatic selection in lesional skin of African American patients with PN. (A)
 Nonsynonymous somatic mutations are ordered by their genomic locations on the x-axis and the
 corresponding VAF is shown on the y-axis. Variants with 0.3 or higher VAF are labelled with their gene
 name. (B and C) Bar graph showing the pathway enrichment results of high-VAF (>0.3) nonsynonymous
 mutations in African American and Caucasian PN patients, respectively.

- 853
- 854

855Figure 3. Co-occurrence and enrichment of recurrent somatic mutations in PN lesional skin. (A)856Somatic mutational correlation matrix of all 46 genes with recurrent nonsynonymous somatic mutations in857PN lesional skin. Significant pairs were identified with Fisher's exact test. (B-D) Gene ontology (GO) term858and pathway enrichment results of recurrently-mutated genes across three pathway databases. Terms859with FDR-corrected P < 0.05 are colored in yellow.

860

861 Figure 4. Somatic mutations in PN and cSCC. (A) Rank order plot showing the somatic mutational 862 burden (number of nonsynonymous mutations occurring per megabase of coding regions) across 17 PN 863 patients and 83 cutaneous squamous cell carcinoma (cSCC) patients. Red dashed line indicates the 864 median mutational burden. Inset is a boxplot comparison of somatic mutational burden between the two 865 cohorts. (B) Boxplot showing VAF of all nonsynonymous somatic variants in cSCC and PN patients. (C) 866 Venn diagram depicting the overlap between known cSCC driver genes, genes that were found mutated 867 in 25% or more of the 83 cSCC samples (cSCC recurrent), and genes that were found mutated in 2 or 868 more of our 17 PN samples (PN lesional recurrent). (D, E) Somatic mutations falling within the NOTCH1 869 and FAT1, respectively. y-axis indicates the number of PN (top) or cSCC (bottom) patients the carrying 870 the somatic mutation. Colored rectangles indicate known functional domains of the protein product. EGF, epidermal growth factor: LamG. laminin G. 871

- 872
- 873

Figure 5. Landscape of somatic CNV in PN. (A) Normalized copy number per sample per chromosome
 for African American and Caucasian patients. (B) Circular plot illustrating the proportion of samples with
 deletions (red) and duplications (blue) per genomic region for African American patients (outer ideogram)

It is made available under a CC-BY-NC-ND 4.0 International license .

877 and Caucasian patients (inner ideogram). (C) Examples of recurrent somatic CNV events only observed 878 in African American patients or Caucasian patients on chromosomes 12 and 15, respectively. (D) RNA-879 seq data was used to determine differentially down- and up-regulated genes in PN lesional skin. 880 Transcript log2 fold-change is shown on the y-axis with respect to genomic location on chromosome 7 on 881 the x-axis. Overlayed red box shows the location of the recurrent 7g21 somatic deletion. (E) GO term 882 enrichment results of 264 genes that overlapped recurrent deletions while also being differentially 883 downregulated in PN lesional skin. Terms with FDR-corrected P < 0.05 are colored in yellow. (F) Decomposition plot showing the relative contributions of CNV signature components to the three somatic 884 885 CNV signatures detected (HomDel: homozygous deletion, LOH: loss-of-heterozygosity). (G) Distribution of CNV signatures in African American and Caucasian PN patients. 886

887

888 Figure 6. Somatic mutational differences between PN and AD. (A) Ten genes with the most frequent 889 nonsynonymous somatic mutations in our AD cohort. (B) All nonsynonymous somatic mutations in AD 890 and PN are ordered by their genomic locations on the x-axis and the corresponding VAF is shown on the 891 y-axis. Variants with 0.3 or higher VAF are labelled with their gene name. (C) Histograms showing the 892 frequency of nonsynonymous somatic variants on the x-axis at the corresponding VAF on the y-axis, in 893 AD and PN. P-value indicates the significant difference in means (Wilcoxon). (D) Mutational diversity per 894 sample using a normalized Shannon Diversity Index based on the VAF of somatic SNVs and indels in PN 895 and AD patients. One hypermutated AD sample was not excluded (see Methods). (E) The top mutated 896 genes in our PN cohort are illustrated, with the corresponding relative frequency and percentage of 897 alteration in AD and PN samples. (F) Rank order plot showing the somatic mutational burden per 898 megabase across 17 PN patients, 9 AD patients, and all 33 cancers in The Cancer Genome Atlas cohort. 899 Red lines indicate the median mutational burden. A dictionary for cancer symbols is included in Table S3 900 (G, H) GO term enrichment results of 21 genes with nonsynonymous somatic mutations in at least two PN 901 samples and no AD samples across two pathway databases. Terms with FDR-corrected P < 0.05 are 902 colored in yellow.

903

904 Figure 7. Somatic mutational signatures in PN and AD. (A) Decomposition plot of the 4 somatic SBS 905 signatures detected showing the relative proportion of each transition and transversion subtype. (B) 906 Distribution of SBS signatures in PN and AD samples. The inset figure shows the relative exposures of 907 mutational signature types. Not shown, but included in all analyses, is a hypermutated AD sample with 908 >20,000 instances of SBS5. (C) Boxplot showing the distribution of SBS signatures in PN compared to 909 AD. (D) Decomposition plot of the two somatic DBS signatures detected showing the relative proportion 910 of each base-pair mutation subtype. (E) Distribution of DBS signatures in PN and AD samples. The inset 911 figure shows the relative exposures of DBS signature types. Samples not shown did not display any 912 known DBS signatures (E) Partial regression plots of DBS1 on each of age, race, itch intensity, and 913 condition (PN versus AD), after controlling for the remaining covariates. Overall model adjusted  $R^2 = 0.66$ .

914

915 Figure 8. Notch signaling is activated in lesional skin of PN patients. (A) IF staining of NICD in 916 lesional and nonlesional skin sections of a PN patient with a NOTCH1 somatic mutation. Representative 917 skin sections are shown at 189-fold magnification of the dermis. NICD (green), DAPI (blue). (B & C) 918 Paired boxplot showing the difference in relative expression of NICD between lesional and nonlesional 919 PN dermis (B) and epidermis (C). (D) IF staining of Notch1 and vimentin in lesional and nonlesional skin 920 sections of a PN patient. Notch1 (red), vimentin (green), DAPI (blue). Representative skin sections are 921 shown at 189-fold magnification of the dermis. (E) Paired boxplot showing the difference in relative co-922 localization of Notch1 and vimentin between PN lesional and nonlesional skin.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 9. Higher risk of *NOTCH1*-associated diseases in PN patients. (A) A multi-center cohort of PN patients and propensity-score matched controls was obtained using the TriNetX Research Network. The top 10 acquired, non-redundant diseases associated with *NOTCH1* were determined based on available literature support using the DisGeNET database (B) Cumulative relative risk of *NOTCH1*-associated diseases in PN patients compared to matched controls. LL/L, lymphoblastic leukemia/lymphoma; H&N SCC, head and neck squamous cell carcinoma; \*\*\*, *P* < 0.0001; ns, no significant difference in risk.</li>





# GO: Biological Process

Mesenchyme development · Mesenchymal cell differentiation · Epithelial tube morphogenesis · Epithelial to mesenchymal transition · Epithelial cell development ·

# С

В

Positive regulation of protein transport · Positive regulation of protein localization · Positive regulation of establishment of protein localization · Manganese ion transmembrane transport · Estrous cycle ·

















Lesional Nonlesional



NOTCH1-associated disease			diff.		
Precursor T-cell LL/L		0.001	***		
Head and neck SCC	<b>⊢</b> ♦−1	0.005	***		
Cervical cancer	<b>⊨ ⊷</b>	0.001	***		
Breast neoplasm	I I∳I	0.01	***		
Bladder cancer	<b>⊢</b> ⊷⊣	0.002	***		
Connective tissue disease	i de l	0.009	***		
Aortic valve calcification	•	0.014	***		
Aortic aneurysm and dissection	l I III	0.007	***		
Adenoid cystic carcinoma	<b>¦→</b>	0	ns		
Glioblastoma	┝╲━┥	0	ns		
0	5 10	)			
Relative risk in PN compared to matched controls					